Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47-60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 (32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (×10 6 cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8-37.6)-13.3 (6.7-22.9) × 10 6 cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1-33.6) × 10 6 cells/g, P = 0.03]. All soluble markers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-α. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers. Chronic Respiratory Disease 2008; 5: 161-168
Introduction
Bronchiectasis is a chronic inflammatory pulmonary disorder characterized by cough and purulent sputum. [1] [2] [3] There is abnormal permanent dilatation of sub-segmental bronchi 3, 4 with impairment of the mucociliary transport system. 5 Inflammation involving T cells, 6 neutrophils, 6, 7 and mast cells 8 is seen in the bronchial mucosa. Airway secretions show inflammatory cell infiltration, predominantly neutrophils [8] [9] [10] but also macrophages and eosinophils 11 with high concentrations of pro-inflammatory mediators. [12] [13] [14] [15] Bronchiectasis is characterized by infection in the airways by organisms such as Pseudomonas aeruginosa, Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis, which are often difficult to eradicate. 16 Exacerbations are frequent 8 and require treatment with antibiotics. 17 Patients often have impaired quality of life (QoL) that deteriorates further with exacerbations. Little is known about the patho-physiological mechanisms of the disorder, the factors affecting QoL, the exacerbations, and the response to treatment. Studies in cystic fibrosis have shown that QoL related well to physiological measurements, 18 but fewer studies have been performed in bronchiectasis. One study reported that dyspnoea, lung function, and sputum production significantly affected QoL in stable bronchiectasis patients, 19 and another study reported that infection with P. aeruginosa was associated with worse QoL in stable bronchiectasis patients. 20 No studies have examined QoL scores in relationship to inflammatory markers during or after a pulmonary exacerbation of bronchiectasis.
The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology, airway inflammation, and systemic inflammation in patients with bronchiectasis at the beginning and after resolution of an exacerbation. patients have been reported by Watt, et al., 21 who examined the effect of treatment of exacerbations on neutrophil apoptosis and necrosis. This analysis was undertaken to examine how changes in these inflammatory mediators influenced QoL.
Subjects
Patients commencing intravenous treatment for an exacerbation of bronchiectasis were recruited. A clinical decision to treat with intravenous antibiotics was made because of increased cough, sputum production, or breathlessness. A diagnosis of bronchiectasis had previously been confirmed by computed tomography scan or bronchography.
Patients were excluded if they had cystic fibrosis, a ciliary disorder, and an immunological abnormality causing bronchiectasis.
Visits
Patients attended for three visits, within 24 h of starting antibiotic treatment (day 0), at the end of 2 weeks treatment with intravenous antibiotics (day 14), and at 4 weeks (day 42) after finishing antibiotics. Patients received standard antimicrobial therapy based upon a combination of recent culture results and severity of illness. Some patients remained in hospital for the duration of their exacerbation, whereas others received some of their treatments (often self administered) at home.
Ethical approval was obtained from the Queen's University Belfast Research Ethics Committee, Belfast, Northern Ireland. Written informed consent was obtained from all participants.
QoL questionnaire
The Chronic Respiratory Disease questionnaire (CRDQ) was used to assess patients' QoL 22 before commencement of sputum induction using standardized methodology. The questionnaire was repeated at each clinic visit. Scores were calculated for each domain of the questionnaire, and a total score was calculated.
Sputum induction, blood test, and sputum processing
On each visit, sputum induction was performed using the Sonix 2000 nebulizer as previously described. 23 Before sputum induction, resting heart rate and oxygen saturations were recorded. C-reactive protein (CRP), immunoglobulins, atypical pneumonia screen, Legionella immunofluorescent antibody titer, aspergillus precipitins, and α-1 antitrypsin concentrations were measured in serum. Blood was sent for full blood count, including differential white cell count (WCC). Sputum was sent for bacteriological analysis to the Belfast City Hospital Bacteriology Department, Belfast, Northern Ireland. Induced sputum was processed and slides were prepared, stained, and counted as previously described. 23 
Soluble markers of inflammation
Supernatants were assayed for interleukin-8 (IL-8), neutrophil elastase (NE), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α). The assays used to measure IL-8, IL-10, and TNF-α were commercially available sandwich ELISAs (Pelikine Compact ELISA kit, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, The Netherlands). NE was assayed as previously described. 23 The detection limits for IL-10, IL-8, TNF-α, and NE were 5 pg/mL, 1 pg/mL, 1 pg/mL, and 30 ng/mL, respectively.
Statistical analysis
Data were expressed as mean (standard error of mean [SEM]) or median (interquartile range [IQR]). Comparisons between visits were performed using either Student's t-test or Wilcoxon matched pairs where appropriate. Unpaired data was analyzed using either the Student's t-test or Mann-Whitney test. Correlation was analyzed using Spearman's Rho. Analysis was performed using SPSS software, version 12.0 (SPSS Inc., Chicago, IL, USA). Significance was assumed if P < 0.05.
Results

Subjects
Eighteen patients with bronchiectasis (12 female) were recruited to the study with a median (IQ range) age of 54 (47-60) years. Of the 18 patients, one was unable to attend on day 42 as there was no period of stability or perceived stability long enough to allow a third visit. One could not be contacted after the first visit. A third patient was unable to attend for subsequent visits for non-clinical reasons. Thus, 15 patients attended for all visits although one patient was unable to produce enough sputum for all the analyses on the third visit.
Twelve patients were using regular inhaled corticosteroids despite the lack of evidence for their effectiveness. 24 Two patients (one with vasculitis and one with a past history of allergic bronchopulmonary aspergillosis) were using regular oral corticosteroids. Four patients also used nebulized colomycin. Two patients were using hypertonic saline as a mucolytic to aid airway clearance. The rest of the medication use reflected co-morbidities.
The commonest noted possible etiologies or associated conditions were tuberculosis, 3 asthma, 3 measles, 4 pertussis, 2 severe pneumonia at some stage of life, 2 severe childhood pneumonia, 2 nontuberculous mycobacterial infection, 1 sinusitis, 2 vasculitis, 1 and a single ∆F508 mutation but normal sweat chloride. 1 All serum immunoglobulin (IgG, IgA, and IgM) and α-1 antitrypsin analysis (levels and phenotype) were normal. All atypical pneumonia and Legionella serology were negative. One patient, known to have past history of allergic bronchopulmonary aspergillosis, was found to have a raised level of aspergillus precipitins (2.0 OD, normal <0.5) in the blood. Table 1 summarizes the changes in lung function and physiology data throughout the study. Although no statistically significant changes occurred, there was a trend towards an improvement in lung function from visit 1 to visit 2, especially with pre-β 2 agonist FEV 1 (L and %). Table 2 summarizes the changes in peripheral blood markers of inflammation. Mean CRP was significantly reduced between visit 1 and 2 and did not increase significantly on visit 3 (Figure 1 ). There was no significant difference between the CRP between visit 1 and visit 3, P = 0.7. Mean white blood cell count was significantly reduced between visit 1 and visit 2 and increased between visit 2 and visit 3 ( Figure 2 ).
Lung function and physiology
Peripheral blood markers of inflammation
Bacteriology
Sputum culture results are showed in Table 3 . Four patients were unable to expectorate sufficient sputum for analysis on either visit 1 or visit 2. All antibiotic regimes were decided on current or the most recent appropriate antibiogram for each patient. Table 4 summarizes the findings from sputum induction. The median (interquartile range) sputum cell count (×10 6 cells/g of sputum) showed a significant decrease from visit 1 to visit 2 and an increase from visit 2 to visit 3. All soluble markers of inflammation were significantly reduced from visit 1 to visit 2. They also increased again at visit 3 although the change for TNF-α failed to reach statistical significance. IL-10 was undetectable in 28 of the total 45 samples assayed. In the remaining samples, a mean (SEM) of 64.4 (±6.29) pg/mL was detected. This is lower than detected in normal subjects (unpublished data).
Sputum analysis
QoL
QoL scores in the four domains of the questionnaire are shown in Table 5 . Four patients were unable to satisfactorily complete the dyspnoea domain of the questionnaire because of their lack of activity while in hospital leading to difficulty in answering questions regarding shortness of breath. Therefore, for these individuals, no changes in dyspnoea could be calculated and so total scores were not calculated. Three of the four domains (dyspnoea, emotional, and mastery) showed significant improvement from visit 1 to visit 2, but there were no significant changes between visit 2 and visit 3. From visit 1 to visit 2, mean dyspnoea score increased 1.1 points, mean emotional score by 0.9 points, and mean mastery score by 0.5 points, all of which represent a clinically significant improvement. There was no relationship between QoL and systemic or pulmonary markers of inflammation or lung function. The change in QoL could not be explained by changes in CRP, lung function, IL-8, or TNF-α ( Table 6 ).
Discussion
This study describes a comprehensive evaluation of patients presenting with acute exacerbations of bronchiectasis. The aim of this study was to investigate changes in QoL of patients with bronchiectasis at the beginning and after treatment of a pulmonary exacerbation and how these were influenced by changes in airway physiology, airway, and systemic inflammation. A number of parameters such as lung function, systemic inflammatory response, QoL, bacteriology, and sputum cellular and soluble markers of infection were studied. Several studies have examined stable bronchiectasis, 7, 9, 20, [25] [26] [27] [28] but the only other previous published study examining exacerbations of bronchiectasis was by Watt, et al., 21 using the same group of patients as our study comparing levels of neutrophil apoptosis and necrosis and inflammatory mediators before and after intravenous antibiotics.
Patients presenting with acute pulmonary exacerbations were studied at the beginning and end of exacerbations and 4 weeks after completion of intravenous antibiotics. There was a significant decrease in systemic markers of inflammation including white cell count and CRP, pulmonary inflammatory indices such as IL-8 and TNF-α in sputum, and increase in QoL scores when comparing pretreatment levels and those levels immediately after 2 weeks of intravenous antibiotics. However, 4 weeks after completion of treatment, markers of inflammation both systemic (WCC) and sputum (IL-8, NE and cell count) deteriorated, in some cases returning to exacerbation levels. QoL scores did not change significantly from visit 2 to visit 3, but the group had a significant worsening in the underlying local and systemic inflammation. These findings show first that patients with bronchiectasis respond to antibiotic therapy with the reduction of inflammation but that this is not sustained with significant increases in both systemic and pulmonary inflammation relatively quickly after finishing intravenous therapy. Previous studies have reported that patients with bronchiectasis can have an active local and systemic inflammatory response even if they have just completed a course of antibiotics or are in a stable phase of their disease. 29, 30 The finding that QoL scores improved in the first 2 weeks of the study but then did not change significantly between day 14 and day 42 implies that improvement in QoL was all gained in the first 2 weeks or that there was a further gain and then loss between day 14 and day 42, which was not captured by the study periods. This is reflected by the fact that both systemic and pulmonary inflammation reduced in the first 2 weeks then had increased by day 42. This is different from exacerbations of chronic obstructive pulmonary disease (COPD), where one study has reported that QoL scores improved rapidly during the first 4 weeks after antibiotic therapy but that slow improvement continued up to 26 weeks post-exacerbation. 31 The difference may reflect a possible difference in the rate of improvement in QoL following an exacerbation between COPD and bronchiectasis or could possibly reflect a quicker return to higher levels of pulmonary inflammation in bronchiectasis.
There was an improvement in all QoL scores except fatigue with intravenous antibiotics, which was sustained for 4 weeks after treatment. This improvement, however, did not correlate with lung function and markers of inflammation (systemic or local) and could not be explained by these parameters. Wilson, et al. 27 studied systemic markers of inflammation in patients with stable bronchiectasis and reported that WCC and CRP correlated with some components of the St Georges Respiratory questionnaire but concluded that there was a weak correlation between markers of inflammation and health related QoL. A study by Martinez-Garcia, et al. 19 examined the QoL determinants in patients with clinically stable bronchiectasis and found that dyspnoea, FEV 1 , and daily sputum production were the main variables that best explained QoL. The same group studied the effect of inhaled steroids on patients with stable bronchiectasis and reported that those patients on inhaled steroids had clinically significant improvements in QoL that could be attributed to reduction in daily sputum production and improved dyspnoea. 28 Wilson, et al. 20 studied patients with bronchiectasis who were in a stable phase of their illness using St Georges Respiratory questionnaire, SF-36, and the Fatigue Scale. They reported that QoL was worse for patients infected with P. aeruginosa chronically in comparison with those who were not infected. They found that the number of infective exacerbations over the previous year significantly correlated with QoL and that this effect was independent of the sputum microbiology. They also reported that oxygen saturation accounted for some variation in QoL measurements but to a lesser extent, whereas the extent of disease on CT scan did not correlate with QoL. 20 A further study examining the validity of the St George's Respiratory questionnaire observed that the number of exacerbations in the previous year was the independent variable exerting the greatest influence on the total QoL. 26 Our study was different to any of the other previous studies in that it examined patients who had an infective exacerbation of their bronchiectasis and studied the QoL scores over a relatively short time period. There were significant improvements in both QoL and inflammationsystemic and pulmonary, pre-and post-intravenous antibiotics; however, there was a lack of relationship between them. This could be for various reasons. First, improvements in inflammation may indirectly improve QoL by affecting other measures such as cough, wheeze, sputum volume, bacterial load, or clearance of the organism, which were not used in our QoL analysis. Second, one component of the QoL questionnaire that is important in this group of patients is the dyspnoea domain, but four patients were unable to complete because of their lack of activity in hospital during their intravenous antibiotic therapy that may affect the results of the QoL analysis and subsequent correlations. Third, the questionnaire chosen to assess QoL in this study was different from some of the above studies. The CRDQ was used as it was designed to assess change in QoL (particularly important in this study), whereas the St Georges questionnaire was designed to measure QoL impairment. 22, 32 The variation in the results from all the above studies including this study emphasizes that QoL measurement is a complex issue, the factors that influence this are poorly understood and that the levels of systemic or pulmonary inflammation are unlikely to be solely responsible for changes in QoL. This then raises questions such as what are the factors that affect QoL in bronchiectasis patients? As a result, what can be done clinically to improve QoL? This study emphasizes the need for a longitudinal study of patients with bronchiectasis over a longer period incorporating both periods of stability and infective exacerbations. It may also be helpful in future studies to examine exercise capacity and sputum volume in their relationship to other parameters and QoL during exacerbations.
There are a number of potential criticisms of this study. The dyspnoea domain of the CRDQ was not answered by all the patients at all the time points because of hospitalization and so may have affected the analysis of QoL. It may have been helpful in this study to look at other parameters that have been shown in stable bronchiectasis patients to correlate with changes in QoL such as sputum volume, presence of wheeze, 6-min walk test, and number of exacerbations in the previous year. The patient sample used in the study is small, and a larger patient cohort may have showed a positive relationship between QoL and some of the parameters studied. Another potential criticism of the study is that patients were recruited when they had an exacerbation rather than when they were stable, and so whether patient achieved their baseline level of inflammation or QoL was unable to be measured.
In summary, this study has characterized a cohort of patients with exacerbations of bronchiectasis reporting improvements in QoL measures and local and systemic inflammation. The improvements in QoL could not be explained by the improvements in inflammatory markers and emphasizes the need for a longitudinal study over a longer period to try and to elucidate the factors that influence QoL in patients with bronchiectasis.
